Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2011

View Archived Issues

GlaxoSmithKline discloses first-in-human data on GSK-2126458 and GSK-2141795

Roche presents new inhibitors of the Mdm2-p53 interaction

Novel hepatocyte growth factor receptor inhibitors patented

Phase II extension trial evaluates continued E-5501 treatment of thrombocytopenia

Phase II ARQ-197 trial assesses safety and efficacy in relapsed/refractory non-CNS germ cell tumors

Pilot study supports tolerability of AC-480 in patients with recurrent malignant glioma

Receptos designs new lysophospholipid S1P1 receptor agonists

Novel chemokine CXCR4 receptor ligands patented

Zealand Pharma and Boehringer Ingelheim join to advance new drugs for type 2 diabetes and obesity

Tradjenta tablets launched in U.S. for type 2 diabetes

BMT-4-159 is a new 17-beta-HSD 5 inhibitor with potential to treat prostate cancer

Orexo completes first clinical study of OX-27 for breakthrough cancer pain

Kareus Therapeutics and Quintiles enter strategic alliance

Data presented from two phase II trials of BCX-4208 with/without allopurinol in gout

AC-201 to enter phase IIb trial in type 2 diabetes

Servier holds option to acquire full Ampakine rights from Cortex Pharmaceuticals

Pronova BioPharma prepares to submit application for PRC-4016 trial in mixed dyslipidemia

New glycogen synthase activators presented

BiondVax reports phase IIa data on Multimeric-001 universal flu vaccine

Sanofi and Audion Therapeutics to develop treatments for hearing loss

MP4OX enters phase IIb trial in patients with trauma and lactic acidosis due to hemorrhagic shock

FDA accepts IntelGenx's resubmission of CPI-300 NDA

Istodax approved in U.S. as therapy for previously treated patients with peripheral T-cell lymphoma

Durasert-based latanoprost delivery implant enters phase I/II trial in patients with elevated IOP

FDA committee to review Seattle Genetic's Adcetris BLAs in July

Bardoxolone methyl enters pivotal trial in patients with chronic kidney disease and type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...